Avantor, Inc. (NYSE:AVTR) Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. lessened its stake in Avantor, Inc. (NYSE:AVTR) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,006 shares of the company’s stock after selling 894 shares during the period. Hantz Financial Services Inc.’s holdings in Avantor were worth $506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. grew its stake in Avantor by 6.9% during the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock worth $170,000 after buying an additional 522 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of Avantor by 0.5% during the fourth quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after acquiring an additional 542 shares during the last quarter. Veracity Capital LLC increased its holdings in shares of Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock valued at $1,355,000 after acquiring an additional 543 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the last quarter. Finally, US Bancorp DE boosted its stake in Avantor by 6.2% during the 3rd quarter. US Bancorp DE now owns 12,615 shares of the company’s stock worth $326,000 after purchasing an additional 734 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. UBS Group reaffirmed a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Raymond James decreased their price objective on Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Robert W. Baird decreased their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Barclays dropped their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Avantor currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Stock Up 0.2 %

AVTR stock opened at $22.26 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The company’s 50-day moving average price is $21.66 and its 200 day moving average price is $23.43. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00. The company has a market cap of $15.15 billion, a P/E ratio of 48.38, a P/E/G ratio of 3.82 and a beta of 1.28.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.